What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study
BACKGROUND:It is unclear what to do when people with type 2 diabetes have had no or a limited glycemic response to a recently introduced medication. Intra-individual HbA1c variability can obscure true response. Some guidelines suggest stopping apparently ineffective therapy, but no studies have addr...
| Κύριοι συγγραφείς: | , , , , , , |
|---|---|
| Άλλοι συγγραφείς: | |
| Μορφή: | Journal article |
| Γλώσσα: | English |
| Έκδοση: |
BioMed Central
2019
|